ライフサイエンスコーパス: balloon

1 from <10% of rats that received the control balloon).

2 ssigned to receive treatment with a standard balloon.

3 compared with rats that received the control balloon.

4 best practice protocol for the endovascular balloon.

5 ears when treatment included an endovascular balloon.

6 esions were treated using the Shockwave C(2) balloon.

7 ent with a drug-coated balloon or a standard balloon.

8 using nets mounted on tethered helium-filled balloons.

9 ty of biocompatible excipients coated on the balloons.

10 terpart of transient apical left ventricular ballooning.

11 xane formation had no effect on synchrony or ballooning.

12 gnificant improvements in both steatosis and ballooning.

13 etween pre-USPIO and post-USPIO T2*) in both ballooning (14.3+/-0.6 milliseconds versus 10.5+/-0.9 mi

14 l Paclitaxel-Coated Percutaneous Angioplasty Balloon), 300 symptomatic patients (Rutherford class 2-4

15 - 0.8; P = 0.014) and presence of hepatocyte ballooning (60.9% vs. 73.4%; P = 0.045).

16 n those who had been treated with a standard balloon (82.2% [125 of 152] vs. 59.5% [88 of 148]; diffe

17 on was done with controlled radial expansion balloons according to common bile duct stone size.

18 ality signal for patients in the drug-coated balloon and drug-eluting stent arms of randomized clinic

19 ure were not significantly different between balloon and self-expandable prostheses.

20 (RCTs) of femoropopliteal paclitaxel-coated balloon and stent intervention identified excess late mo

21 iated with a significant increase in door-to-balloon and total ischemia times, which may have contrib

22 erapeutic L1-10 treatment reduced hepatocyte ballooning and fibrosis in MCD diet-fed mice and was ass

23 atosis, lobular inflammation, hepatocellular ballooning and fibrosis stage.

24 as more severe fat accumulation, hepatocyte ballooning and inflammation infiltrate.

25 the three histological determinants of NASH, ballooning and inflammation, but not steatosis, were ind

26 , is significantly associated with decreased ballooning and inflammation.

27 epatitis was based on presence of steatosis, ballooning and perisinusoidal fibrosis.

28 Paclitaxel drug-coated balloons and drug-eluting stents became commercially ava

29 ith the use of paclitaxel-coated angioplasty balloons and stents in lower-limb endovascular intervent

30 of heterogeneous trials of paclitaxel-based balloons and stents reported that they are associated wi

31 cible and show steatohepatitis (ideally with ballooning) and at least focal bridging fibrosis, while

32 gned to receive treatment with a drug-coated balloon, and 160 were assigned to receive treatment with

33 rior vena cava using an esophageal deviation balloon, and ablation was performed from within the infe

34 n, characterized by mesangiolysis, capillary ballooning, and albuminuria.

35 cal severity of liver disease (inflammation, ballooning, and fibrosis) was not associated with the am

36 he STAM mice developed steatosis, hepatocyte ballooning, and inflammation, which were significantly r

37 tional emergence of inflammation, hepatocyte ballooning, and liver fibrosis.

38 analyses, mortality was similar after plain balloon angioplasty (12.6%) and paclitaxel-coated balloo

39 on angioplasty (12.6%) and paclitaxel-coated balloon angioplasty (9.6%; HR=0.84 [95% CI, 0.66-1.06],

40 f DCB angioplasty compared with conventional balloon angioplasty (also known as plain old balloon ang

41 ions were randomized to treatment with plain balloon angioplasty (BA) followed by PEB angioplasty and

42 rtality was compared between 3 groups; plain balloon angioplasty (N=2104) versus paclitaxel-coated ba

43 ngioplasty (N=2104) versus paclitaxel-coated balloon angioplasty (N=3543), bare-metal stenting (N= 20

44 a focus on lesion modification to facilitate balloon angioplasty and stenting has underpinned major a

45 The efficacy of balloon angioplasty for native CoA during infancy beyond

46 ospective review of 68 infants who underwent balloon angioplasty for native CoA.

47 Balloon angioplasty for native coarctation of the aorta

48 ACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Fem

49 Balloon angioplasty increased the CoA diameter from 2.7+

50 Common carotid artery (CCA) balloon angioplasty injury was performed in rats.

51 vascular response to injury in a rat carotid balloon angioplasty model.

52 Balloon angioplasty of native CoA is effective and safe

53 balloon angioplasty (also known as plain old balloon angioplasty or POBA).

54 62.7% (95% CI: 50.0%, 73.0%) of conventional balloon angioplasty participants (P < .001).

55 d 78% (95% CI: 66.5%, 86.0%) of conventional balloon angioplasty participants (P = .001).

56 One DCB angioplasty and two conventional balloon angioplasty participants died (risk ratio, 0.48;

57 Balloon angioplasty produced a large decrease in both th

58 Balloon angioplasty was limited by unpredictable procedu

59 Drug-coated balloon angioplasty was superior to standard angioplasty

60 derwent successful percutaneous transluminal balloon angioplasty with an iodinated contrast medium (2

61 (Paclitaxel-Eluting Balloon Angioplasty With Provisional Use of Nitinol Sten

62 B with non-DCB devices (such as conventional balloon angioplasty, bare-metal stents, or drug-eluting

63 ts underwent DCB angioplasty or conventional balloon angioplasty.

64 tes for both strategies compared to standard balloon angioplasty.

65 remained superior compared with conventional balloon angioplasty.

66 riority of DCB angioplasty over conventional balloon angioplasty.

67 eplacement (TAVR) led to renewed interest in balloon aortic valvuloplasty (BAV).

68 s indicated that use of the BVS, female sex, balloon-artery ratio >1.25, expansion index >/=0.8, prev

69 ry, interactions between the coating and the balloon as well as site-specific differences, have led t

70 n the overall cohort treated with coiling or balloon-assisted coiling for a single aneurysm.

71 urysm risk factors after aneurysm coiling or balloon-assisted coiling within the Analysis of Recanali

72 g wide-necked bifurcation aneurysms, such as balloon-assisted coiling, stent-assisted coiling, waffle

73 Conclusion During aneurysm coiling or balloon-assisted coiling, thromboembolic events were mor

74 our controller to station Loon superpressure balloons at multiple locations across the globe, includi

75 lesions that uses acoustic shock waves in a balloon-based system to induce fracture in the calcium d

76 gn and the limitations of currently accepted balloon-borne analysis techniques for the detection of s

77 (eclipse waves #2 and #3 respectively) using balloon-borne radiosondes.

78 The compliant radiofrequency balloon can directionally tailor energy delivery for eff

79 An endovascular balloon can occlude the SVC in the event of a laceration

80 After balloon catheter injury, neointimal hyperplasia was sign

81 by stepwise volume expansion of an epidural balloon catheter until negative cerebral perfusion press

82 Percutaneous Transluminal Angioplasty [PTA] Balloon Catheter vs Standard PTA for the Treatment of At

83 al mapping, a novel compliant radiofrequency balloon catheter with 10 irrigated, flexible electrodes

84 in multilayer configurations on endocardial balloon catheters can establish conformal contact with c

85 Balloon catheters facilitate pulmonary vein (PV) isolati

86 In some FCD subtypes, balloon cells express proteins typically seen in neurogl

87 binucleation, which are typical features of balloon cells.

88 lloon [intracranial air (ICA)], water-filled balloon (cerebrospinal fluid and blood) and agarose gel

89 A DCB consists of a semicompliant balloon coated with antiproliferative agents encapsulate

90 mini-robot for colonoscopy consisting of two balloons connected by a 3 degrees of freedom soft pneuma

91 tion between hospital performance on door-to-balloon (D2B) time for STEMI and door-to-needle (DTN) ti

92 hospitals' proportion of cases with door-to-balloon (D2B) time under 90 minutes.

93 ials confirm that the paclitaxel drug-coated balloon (DCB) (IN.PACT Admiral, Medtronic, Dublin, Irela

94 demonstrated the superiority of drug-coated balloon (DCB) angioplasty versus standard percutaneous t

95 sion At 2 years after paclitaxel drug-coated balloon (DCB) angioplasty, primary patency and freedom f

96 Background Paclitaxel drug-coated balloon (DCB) catheter angioplasty is the preferred trea

97 ated the safety of the Stellarex drug-coated balloon (DCB) for femoropopliteal artery disease with an

98 t-based local drug delivery by a drug-coated balloon (DCB) has been investigated, as it leaves no met

99 The hallmark of drug-coated balloon (DCB) therapy for the treatment of peripheral va

100 of drug-eluting stents (DES) and drug-coated balloons (DCB) for femoropopliteal interventions reporte

101 Studies assessing drug-coated balloons (DCB) for the treatment of femoropopliteal arte

102 w data on the comparison between drug-coated balloons (DCBs) and drug-eluting stents (DES) are availa

103 Drug-coated balloons (DCBs) are accepted treatment strategies for co

104 interest in the application of drug eluting balloons (DEB) as counteractive measures for intralumina

105 onged dilation (300 s) with a 10 mm diameter balloon decreases the occurrence of pancreatitis after e

106 ic SHH expression correlated with histologic ballooning degeneration (rho = 0.62, p < 0.0001), steato

107 AGER1 levels were associated with hepatocyte ballooning degeneration and ductular reaction.

108 osteatosis, lobular inflammation, hepatocyte ballooning degeneration and periportal/perisinusoidal fi

109 acantholysis in the squamous epithelium and ballooning degeneration of and intranuclear inclusion bo

110 etry (CAM) can be used to assess severity of ballooning degeneration.

111 ly consistent linkage between longer door-to-balloon delay and higher risk of adverse outcomes at the

112 38.0% (1651) experienced a door-to-balloon delay of >90 minutes.

113 derwent PV isolation with the radiofrequency balloon delivered over-the-wire with a deflectable 13.5F

114 Drug-coated balloons delivering the antirestenotic agent paclitaxel

115 ariate regression modeling found that proper balloon deployment was an independent, negative predicto

116 olerability of the procedure, we optimized a balloon device (OriCol) for rectal microbiome sampling r

117 The balloon device was acceptable among 23 participants, as

118 with calcified lesions in which noncompliant balloon dilatation failed (n=22 lesions), and (group C)

119 phincterotomy (EST) and endoscopic papillary balloon dilation (EPBD) can be challenging, requiring me

120 limited EST plus endoscopic papillary large balloon dilation (EST-EPLBD) for large bile duct stone e

121 post-ERCP pancreatitis compared with shorter balloon dilation (p=0.002).

122 ere randomly assigned (1:1:1:1:1) to receive balloon dilation for 0, 30, 60, 180, or 300 s after deep

123 ET prior to new surgical treatments, such as balloon dilation for middle ear diseases.

124 n for combined endoscopic sphincterotomy and balloon dilation for the removal of common bile duct sto

125 Balloon dilation offers an alternative.

126 of patients undergoing aortic interventions (balloon dilation or Ross) were assessed longitudinally.

127 s for combined endoscopic sphincterotomy and balloon dilation reduced the frequency of post-ERCP panc

128 A balloon dilation time of 30 s for combined endoscopic sp

129 Balloon dilation was done with controlled radial expansi

130 used for MR imaging-guided catheterization, balloon dilation, and stent implantation into aorto-ilia

131 The RUPV was protected with a high-pressure balloon during stent implantation to prevent pulmonary v

132 Mean procedure, balloon dwell, and fluoroscopy times were 101.6, 40.5, a

133 Such a squeezed balloon effect strengthens the G-tetrad planes, but disl

134 calculated from experiments with a catheter balloon embedded in a plastisol phantom at multiple infl

135 Examination by single-balloon enteroscopy revealed a polyp with long pedicle l

136 No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transca

137 r the initial learning curve (LC), a VOR for balloon-expandable (BE) TAVR persisted; and 2) to determ

138 e the outcomes of TAVR according to Sapien 3 balloon-expandable (BE) versus Evolut R self-expanding T

139 aim to compare the safety and performance of balloon-expandable and self-expandable transcatheter hea

140 oston Scientific Lotus valve (Lotus) and the balloon-expandable Edwards Sapien 3 (ES3) valve.

141 lly available valve (either an intra-annular balloon-expandable Edwards-SAPIEN, SAPIEN XT, or SAPIEN

142 did not meet non-inferiority compared to the balloon-expandable SAPIEN 3 device in terms of early saf

143 f-expanding ACURATE neo TAVR system with the balloon-expandable SAPIEN 3 TAVR system with regard to e

144 me) European registry for treatment with the balloon-expandable SAPIEN 3 transcatheter heart valve an

145 to undergo either transfemoral TAVR with the balloon-expandable SAPIEN 3 valve or SAVR.

146 which encircles the chordae tendineae, and a balloon-expandable transcatheter heart valve.

147 f PVR following TAVR with a third-generation balloon-expandable transcatheter heart valve.

148 nce of new-generation self-expandable versus balloon-expandable transcatheter heart valves in bicuspi

149 MViV using aortic balloon-expandable transcatheter heart valves is associa

150 s of patients with IE post-TAVR treated with balloon-expandable valve (BEV) versus self-expanding val

151 tched cohort, although patients treated with balloon-expandable valve had a higher rate of annular ru

152 d with SAVR, the second-generation SAPIEN XT balloon-expandable valve has a higher 5-year rate of SVD

153 needed at 3-year follow-up after TAVI with a balloon-expandable valve in 3.5% of patients and was suc

154 were randomized to transfemoral TAVR using a balloon-expandable valve or surgery in the PARTNER 3 (Pl

155 either TAVR with transfemoral placement of a balloon-expandable valve or surgery.

156 A balloon-expandable valve was used in 83.7% of cases.

157 self-expandable valve and 80 (34.7%) with a balloon-expandable valve.

158 of Second-Generation Self-Expandable Versus Balloon-Expandable Valves and General Versus Local Anest

159 TranscathetER aortic valve implantation with balloon-expandable valves versus self-expandable valves)

160 Acute outcomes after TPVR with balloon-expandable valves were generally excellent in al

161 ools to evaluate DD-a clinical DD score, the balloon expulsion test (BET) and a digital rectal examin

162 h geometries that resemble hemispheres, fire balloons, flowers, concave lenses, saddle surfaces, wate

163 the Zilver PTX Stent vs. Paclitaxel-Eluting Balloons for Treatment of Symptomatic Peripheral Artery

164 coronary intervention with paclitaxel-coated balloons from randomized controlled trials (RCTs).

165 e treatment effect compared with an uncoated balloon has differed greatly among the randomized trials

166 ch Perfusion (SAAP) combines thoracic aortic balloon hemorrhage control with intra-aortic oxygenated

167 y Using the IN.PACT Admiral(TM) Drug-Eluting Balloon in a Chinese Patient Population, NCT02118532; an

168 d short-term efficacy of this radiofrequency balloon in a multicenter, single-arm, first-in-human stu

169 Ischemia was induced by inflating a balloon in the left anterior descending artery between t

170 Efficiently navigating a superpressure balloon in the stratosphere(1) requires the integration

171 This is a report of platelet ballooning in human disease and of a previously unrecogn

172 l that in aggregates of platelets in plasma, ballooning in multiple platelets occurs in a synchronise

173 ospective study to evaluate the ability of a balloon-incorporated MI catheter to detect and evaluate

174 peptin in the first hours after experimental balloon-induced ischemia in humans.

175 went surgical repair (0.8%), and 2 underwent balloon inflation (0.8%).

176 Blood was collected before balloon inflation (baseline) every 15 minutes for the fi

177 However, unopposed balloon inflation in the distal thoracic aorta for 60 mi

178 e poor drug delivery efficiency due to short balloon inflation times (30-60 s) that limit the passive

179 rd ischemia, an effect mitigated by limiting balloon inflation to 30 minutes.

180 Balloon inflation uniformly improved hemodynamics and wa

181 Homer1 expression levels are upregulated in balloon-injured vs. uninjured VSMCs.

182 alcification on neointimal hyperplasia after balloon injury in the rat carotid.

183 and upregulated after 5 days in rat carotid balloon injury model, with positive correlation to PDGFB

184 Transesophageal echocardiography and balloon interrogation identified 60% of the patients wit

185 Balloon interrogation of cavoatrial junction confirmed c

186 r transesophageal echocardiography underwent balloon interrogation with monitoring of right upper pul

187 nsists of an acrylic box (skull), air-filled balloon [intracranial air (ICA)], water-filled balloon (

188 quency energy or single-application one-shot balloons is either technically challenging or have limit

189 Human platelet transformation into balloons is part of the haemostatic response and thrombu

190 The radiofrequency balloon isolated all targeted PVs (152/152), 79.6% with

191 VA), defined as either vertebroplasty and/or balloon kyphoplasty (BKP), is a minimally invasive surgi

192 Balloon kyphoplasty provided mortality benefits over ver

193 al colon macrophages that are equipped with "balloon-like" protrusions (BLPs) inserted in the epithel

194 reased steatosis but decreased inflammation, ballooning, Mallory-Denk bodies, and liver enzyme levels

195 ibrosis for both studies included steatosis, ballooning, Mallory-Denk bodies, and portal, but not lob

196 We developed a balloon MI catheter system that instantly detects change

197 e (AUC) were used to compare the accuracy of balloon MI in diagnosis.

198 g the left gastric artery using an occlusion balloon microcatheter to administer 300- to 500-mum embo

199 ral stenosis often benefit from percutaneous balloon mitral valvuloplasty.

200 We therefore developed a balloon mucosal impedance (MI) catheter system that inst

201 ronary artery (RCA) and left coronary artery balloon occlusion at baseline before and at follow-up ex

202 erformed ischemia-reperfusion injuries using balloon occlusion for 60 minutes followed by a 3-, 7-, o

203 different durations of experimental coronary balloon occlusion in humans.

204 Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) has been used cli

205 Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a novel strate

206 Resuscitative endovascular balloon occlusion of the aorta (REBOA) is an innovative

207 induced in nondiabetic pigs (n = 14) by 2-h balloon occlusion of the proximal left anterior descendi

208 trol pigs (n=5) and pigs following 90-minute balloon occlusion-induced ischemia/reperfusion (I/R) of

209 after primary PCI via 4 cycles of 30 seconds balloon occlusions followed by 30 seconds of reperfusion

210 nditioning performed as 4 repeated 30-second balloon occlusions followed by 30 seconds of reperfusion

211 n the same external force was applied by the balloon on the arterial wall.

212 gned to receive treatment with a drug-coated balloon or a standard balloon.

213 undergo catheter ablation with a cryothermy balloon or to receive antiarrhythmic drug therapy for in

214 Stones were removed using stone retrieval balloons or baskets.

215 udy of the Stellarex Drug-Coated Angioplasty Balloon), paclitaxel plasma concentrations were measured

216 Paclitaxel coated balloons (PCBs) are a promising non-implantable alternat

217 Paclitaxel-eluting balloon (PEB) angioplasty, stenting, and directional ath

218 ent modalities are scoring and high-pressure balloons, percutaneous coronary intervention with additi

219 Ballooning platelets were decorated with histone H4, a d

220 ter VIV TAVR by inflation of a high-pressure balloon positioned across the valve ring during rapid ve

221 The aim of this study was to compare, after balloon pre-dilation, a strategy of DCB followed by prov

222 few dirhodium carboxylates (5 mol %) under a balloon pressure of oxygen.

223 The balloons provide anchorage into the colonic wall for a b

224 ble CTEPH) include pulmonary vasodilators or balloon pulmonary angioplasty (BPA).

225 al hypertension-targeted pharmacotherapy and balloon pulmonary angioplasty represent potential therap

226 ects should be evaluated for endarterectomy, balloon pulmonary angioplasty, or vasodilator therapies.

227 ere less likely supported by an intra-aortic balloon pump (3.3% versus 3.8%; P=0.03) or durable ventr

228 he Impella device compared with intra-aortic balloon pump (IABP) and medical treatment in patients wi

229 ding strategy while on VA-ECMO (intra-aortic balloon pump 91.7%, percutaneous ventricular assist devi

230 ly revascularization and use of intra-aortic balloon pump counterpulsation therapy, the prognosis of

231 mercially available devices-the intra-aortic balloon pump counterpulsation, the Impella system, the T

232 place before the procedure was intra-aortic balloon pump in 14 patients (67%), Impella CP in 2, extr

233 poreal membrane oxygenation and intra-aortic balloon pump in 2, and extracorporeal membrane oxygenati

234 Using IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock II) trial inclusion an

235 derived from the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) trial.

236 e in our ICU (67% of them had an intraaortic balloon pump to unload the left ventricle).

237 rane oxygenation (11%), although intraaortic balloon pump use also varied between centers (range: 40%

238 Patients managed with intraaortic balloon pump versus other forms of MCS (advanced MCS) ha

239 I) treated with MCS (Impella or intra-aortic balloon pump).

240 utaneous coronary intervention, intra-aortic balloon pump, and percutaneous left ventricular assist d

241 utaneous coronary intervention, intra-aortic balloon pump, and percutaneous LVAD), in-hospital mortal

242 utaneous coronary intervention, intra-aortic balloon pump, and percutaneous LVAD).

243 ross-clamp and operation times, intra-aortic balloon pump, blood products and resternotomy.

244 Compared with intra-aortic balloon pump, Impella provides greater hemodynamic suppo

245 operative use of beta-blockers, intra-aortic balloon pump, or catecholamines.

246 predominant form of MCS use is intra-aortic balloon pump.

247 cent (2808/3301) of MCS use was intra-aortic balloon pump.

248 vention was performed in 23.1%; intra-aortic balloon pump/percutaneous LVAD was used in 57.9%, of whi

249 of percutaneous MCS (including intra-aortic balloon pumping, Impella, TandemHeart, and extracorporea

250 l membrane oxygenation (+1.2%), intra-aortic balloon pumps (+ 4 %), and exceptions (+ 12%).

251 ommon temporary MCS devices were intraaortic balloon pumps (72%), Impella (17%), and veno-arterial ex

252 ynamic support as compared with intra-aortic balloon pumps (IABPs), little is known about clinical ou

253 (OHT) in patients bridged with intra-aortic balloon pumps (IABPs).

254 corporeal membrane oxygenation, intra-aortic balloon pumps, and exception requests and fewer candidat

255 ker with apoptosis and liver damage, such as ballooning (r = 0.65; P < 0.001), followed by lobular in

256 noted fluoroscopically when the waist of the balloon released and by a sudden drop in inflation press

257 e mechanism underlying synchronised membrane ballooning requires thrombin generation acting effective

258 studies undertaken using an intraventricular balloon revealed no detrimental effects of mexiletine (1

259 Seven Shockwave balloons ruptured during treatment without any sequelae.

260 udy reports a Soft Pneumatic Inchworm Double balloon (SPID) mini-robot for colonoscopy consisting of

261 ation of the G-quadruplex, which resembles a balloon squeezed in certain directions.

262 r operating characteristics curves to detect ballooning, steatosis, or steatohepatitis (SH) were slig

263 Patients in the stent-only versus balloon-stent group had similar baseline characteristics

264 -term follow-up in the stent-only versus the balloon-stent group; however, the incidence of stent thr

265 Patients were stratified into stent-only and balloon-stent groups.

266 at limit the passive drug diffusion from the balloon surface to the luminal lesion.

267 e devices alone in 61%, stent grafts in 17%, balloon tamponade facilitated closure in 15%, and planne

268 ammation (taurolithocholate), and hepatocyte ballooning (taurocholate).

269 The procedure involved balloon test inflation in the anticipated stent landing

270 ants who had been treated with a drug-coated balloon than in those who had been treated with a standa

271 or PCI, transradial primary PCI, and door-to-balloon time add incremental prognostic value in STEMI c

272 a larger infarct size and longer symptom-to-balloon time in G-CSF patients.

273 ems of care from a singular focus on door-to-balloon time to a comprehensive focus on multifaceted ST

274 Literature studying the door-to-balloon time-outcome relation in coronary intervention i

275 of transradial primary PCI, and (3) door-to-balloon time.

276 exposure variable was patient-level door-to-balloon time.

277 e traditionally focused on improving door-to-balloon time.

278 globin and troponin on admission, symptom-to-balloon-time and LVEF were predictors of 1-year HHF.

279 n=25) protocols with respective mean door-to-balloon times of 72 versus 97 minutes.

280 Then, cold water was infused into the balloon to cool the pancreas.

281 Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patenc

282 opic retrograde cholangiopancreatography and balloon trawling of the intraductal lesions extracted ne

283 e identified, of which 44.0% involved proper balloon use and 56.0% involved no use or improper use.

284 laser or mechanical atherectomy, drug-coated balloons, vascular brachytherapy, and surgical revascula

285 The BEAT (balloon versus self-expandable valve for the treatment o

286 ized Trial of IN.PACT Admiral(R) Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Pro

287 I], NCT01175850; IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatme

288 SFA II], NCT01566461; MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atheroscle

289 mparison to 37 of 65 patients (56.9%) when a balloon was not used or improperly used (P=0.0002).

290 When an endovascular balloon was properly used, 45 of 51 patients (88.2%) sur

291 An un-perfused balloon was used as a control.

292 Importantly, synchronised ballooning was closely followed by a surge in microvesic

293 contrary, use of coronary paclitaxel-coated balloons was associated with a trend toward lower mortal

294 timal M30 cut-off values for mild and severe ballooning were 330 and 420 U/L, and 290 and 330 U/L for

295 Drug-coated balloons were noninferior to standard balloons with resp

296 Some models demonstrate hepatocyte ballooning, which can be confused with microvesicular st

297 A urethane balloon with 2 polyurethane tubes was placed inside the

298 cluding steatosis, lobular inflammation, and ballooning with or without peri-sinusoidal fibrosis.

299 coated balloons were noninferior to standard balloons with respect to the primary safety end point (4

300 platelets are transformed into procoagulant balloons within minutes of injury, accompanied by the re